{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:52:45Z","timestamp":1790985165440,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["annalsofvascularsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Vascular Surgery"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.avsg.2025.04.110","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T11:05:00Z","timestamp":1744974300000},"page":"68-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Contemporary Femoropopliteal Stents: Reporting Gaps of Randomized Trials"],"prefix":"10.1016","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1942-911X","authenticated-orcid":false,"given":"Stefanos","family":"Giannopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Volteas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Koudounas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Virvilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-1582","authenticated-orcid":false,"given":"Nicos","family":"Labropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.avsg.2025.04.110_bib1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.avsg.2025.04.110_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.gheart.2013.12.008","article-title":"Global and regional burden of death and disability from peripheral artery disease: 21 world regions, 1990 to 2010","volume":"9","author":"Sampson","year":"2014","journal-title":"Glob Heart"},{"key":"10.1016\/j.avsg.2025.04.110_bib3","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jacc.2016.11.008","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of cardiology\/American heart association task force on clinical practice guidelines","volume":"69","author":"Gerhard-Herman","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2025.04.110_bib4","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1161\/CIRCULATIONAHA.105.593442","article-title":"Peripheral arterial disease: morbidity and mortality implications","volume":"114","author":"Golomb","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2025.04.110_bib5","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.2337\/diacare.26.12.3333","article-title":"Peripheral arterial disease in people with diabetes","volume":"26","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.avsg.2025.04.110_bib6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0140-6736(13)61752-3","article-title":"The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective","volume":"383","author":"Mahmood","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.avsg.2025.04.110_bib7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jama.292.4.453","article-title":"Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms","volume":"292","author":"McDermott","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.avsg.2025.04.110_bib8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.avsg.2025.04.110_bib9","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.jacc.2008.07.060","article-title":"Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality","volume":"52","author":"Criqui","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2025.04.110_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1056\/NEJM199202063260605","article-title":"Mortality over a period of 10 years in patients with peripheral arterial disease","volume":"326","author":"Criqui","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2025.04.110_bib11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1583\/11-3539.1","article-title":"Endovascular management as first therapy for chronic total occlusion of the lower extremity arteries: comparison of balloon angioplasty, stenting, and directional atherectomy","volume":"18","author":"Gallagher","year":"2011","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.avsg.2025.04.110_bib12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/1526602816650206","article-title":"Twelve-Month results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for treatment of obstructive femoropopliteal disease","volume":"23","author":"Muller-Hulsbeck","year":"2016","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.avsg.2025.04.110_bib13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jcin.2018.03.046","article-title":"1-Year all-comers analysis of the Eluvia drug-eluting stent for long femoropopliteal lesions after suboptimal angioplasty","volume":"11","author":"Bisdas","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2025.04.110_bib14","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(18)32262-1","article-title":"A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial","volume":"392","author":"Gray","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.avsg.2025.04.110_bib15","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1080\/17425247.2016.1230098","article-title":"Eluvia peripheral stent system for the treatment of peripheral lesions above the knee","volume":"13","author":"Muller-Hulsbeck","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.avsg.2025.04.110_bib16","author":"Wells"},{"key":"10.1016\/j.avsg.2025.04.110_bib17","doi-asserted-by":"crossref","first-page":"e12449","DOI":"10.1097\/MD.0000000000012449","article-title":"Viabahn stent graft compared with prosthetic surgical above-knee bypass in treatment of superficial femoral artery disease: long-term results of a retrospective analysis","volume":"97","author":"Waezi","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.avsg.2025.04.110_bib18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/15266028211067739","article-title":"Twelve-Month outcomes from the Japanese post-market surveillance study of the Viabahn endoprosthesis as treatment for symptomatic peripheral arterial disease in the superficial femoral arteries","volume":"29","author":"Iida","year":"2022","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.avsg.2025.04.110_bib19","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jcin.2014.05.008","article-title":"Drug delivering technology for endovascular management of infrainguinal peripheral artery disease","volume":"7","author":"Sarode","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2025.04.110_bib20","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00270-021-02901-6","article-title":"24-Month efficacy and safety results from Japanese patients in the IMPERIAL randomized study of the Eluvia drug-eluting stent and the zilver PTX drug-coated stent","volume":"44","author":"Iida","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.avsg.2025.04.110_bib21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1177\/15266028211049339","article-title":"Clinical outcome of drug-eluted stenting (zilver PTX) in patients with femoropopliteal occlusive disease a single center experience","volume":"29","author":"AbuRahma","year":"2022","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.avsg.2025.04.110_bib22","first-page":"123","article-title":"The natural history of claudication: risk to life and limb","volume":"12","author":"Dormandy","year":"1999","journal-title":"Semin Vasc Surg"},{"key":"10.1016\/j.avsg.2025.04.110_bib23","doi-asserted-by":"crossref","first-page":"2s","DOI":"10.1016\/j.jvs.2014.12.009","article-title":"Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication","volume":"61","author":"Conte","year":"2015","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2025.04.110_bib24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jacc.2018.10.002","volume":"73","author":"Bailey","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2025.04.110_bib25","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2019.05.006","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"58","author":"Conte","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.avsg.2025.04.110_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jvs.2019.05.005","article-title":"Overuse of early peripheral vascular interventions for claudication","volume":"71","author":"Hicks","year":"2020","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2025.04.110_bib27","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.jvs.2023.04.023","article-title":"Reprint of: early peripheral vascular interventions for claudication are associated with higher rates of late interventions and progression to chronic limb threatening ischemia","volume":"77","author":"Sorber","year":"2023","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2025.04.110_bib28","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jvs.2019.01.060","article-title":"Impact of office-based laboratories on physician practice patterns and outcomes after percutaneous vascular interventions for peripheral artery disease","volume":"70","author":"Itoga","year":"2019","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2025.04.110_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejvs.2023.08.066","article-title":"Exploring the reporting standards of randomised controlled trials involving endovascular interventions for peripheral arterial disease: a systematic review","volume":"67","author":"Zywicka","year":"2024","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.avsg.2025.04.110_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M17-0046","article-title":"CONSORT statement for randomized trials of nonpharmacologic treatments: a 2017 update and a consort extension for nonpharmacologic trial abstracts","volume":"167","author":"Boutron","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.avsg.2025.04.110_bib31","doi-asserted-by":"crossref","first-page":"g1687","DOI":"10.1136\/bmj.g1687","article-title":"Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide","volume":"348","author":"Hoffmann","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.avsg.2025.04.110_bib32","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1161\/CIRCULATIONAHA.122.059606","article-title":"Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: primary results of the EMINENT randomized trial","volume":"146","author":"Gou\u00ebffic","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2025.04.110_bib33","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00270-020-02693-1","article-title":"Two-year efficacy and safety results from the IMPERIAL randomized study of the Eluvia polymer-coated drug-eluting stent and the zilver PTX polymer-free drug-coated stent","volume":"44","author":"M\u00fcller-H\u00fclsbeck","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.avsg.2025.04.110_bib34","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jcin.2019.12.028","article-title":"A polymer-free paclitaxel-eluting stent versus a bare-metal stent for de novo femoropopliteal lesions: the BATTLE trial","volume":"13","author":"Gou\u00ebffic","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2025.04.110_bib35","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2018.11.039","article-title":"Drug-eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterial disease","volume":"73","author":"Bausback","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2025.04.110_bib36","first-page":"679","article-title":"Drug coated balloon supported Supera stent versus Supera stent in intermediate and long-segment lesions of the superficial femoral artery: 2-year results of the RAPID Trial","volume":"60","author":"de Boer","year":"2019","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"10.1016\/j.avsg.2025.04.110_bib37","doi-asserted-by":"crossref","first-page":"e006564","DOI":"10.1161\/CIRCINTERVENTIONS.118.006564","article-title":"Drug-eluting versus bare-metal stent implantation with or without cilostazol in the treatment of the superficial femoral artery","volume":"11","author":"Miura","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2025.04.110_bib38","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1177\/1526602817725062","article-title":"Short-term results of the RAPID randomized trial of the legflow paclitaxel-eluting balloon with Supera stenting vs Supera stenting alone for the treatment of intermediate and long superficial femoral artery lesions","volume":"24","author":"de Boer","year":"2017","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.avsg.2025.04.110_bib39","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.115.016900","article-title":"Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the zilver PTX randomized trial","volume":"133","author":"Dake","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2025.04.110_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00270-014-1024-9","article-title":"Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial","volume":"38","author":"Lammer","year":"2015","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.avsg.2025.04.110_bib41","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.jacc.2013.03.034","article-title":"Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies","volume":"61","author":"Dake","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2025.04.110_bib42","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jvs.2013.01.050","article-title":"Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease","volume":"58","author":"Geraghty","year":"2013","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2025.04.110_bib43","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jacc.2013.05.079","volume":"62","author":"Lammer","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2025.04.110_bib44","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/CIRCINTERVENTIONS.111.962324","article-title":"Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results","volume":"4","author":"Dake","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2025.04.110_bib45","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jvir.2008.02.008","article-title":"Randomized, multicenter study comparing expanded polytetrafluoroethylene-covered endoprosthesis placement with percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease","volume":"19","author":"Saxon","year":"2008","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.avsg.2025.04.110_bib46","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jcin.2021.03.035","article-title":"Assessment of 5-year mortality outcomes for femoropoliteal interventions using drug-eluting devices in the REAL-PTX study","volume":"14","author":"Wittig","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2025.04.110_bib47","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/15385744231171746","article-title":"Randomized clinical trial comparing drug eluting stent zilver PTX\u00ae versus bare metal stent zilver Flex\u00ae for treatment of lesions in femoral and popliteal arteries in chronic limb threatening ischemia","volume":"57","author":"Fransson","year":"2023","journal-title":"Vasc Endovascular Surg"},{"key":"10.1016\/j.avsg.2025.04.110_bib48","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.avsg.2025.04.110_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.avsg.2025.04.110_bib50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.avsg.2025.04.110_bib51","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ccd.27635","article-title":"SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions","volume":"92","author":"Feldman","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2025.04.110_bib52","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2025.04.110_bib53","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/CIRCINTERVENTIONS.112.971630","article-title":"Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial","volume":"5","author":"Werk","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2025.04.110_bib54","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1583\/13-4630MR.1","article-title":"Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions","volume":"21","author":"Zeller","year":"2014","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.avsg.2025.04.110_bib55","doi-asserted-by":"crossref","first-page":"1s","DOI":"10.1016\/j.jvs.2014.12.006","article-title":"Society for Vascular Surgery Practice guidelines for atherosclerotic occlusive disease of the lower extremities management of asymptomatic disease and claudication. Introduction","volume":"61","author":"Conte","year":"2015","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2025.04.110_bib56","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.105.605246","article-title":"Physical activity during daily life and mortality in patients with peripheral arterial disease","volume":"114","author":"Garg","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2025.04.110_bib57","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1253\/circj.CJ-17-1156","article-title":"Registry assessment of peripheral interventional devices (RAPID) - registry assessment of peripheral interventional devices core data elements","volume":"82","author":"Jones","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.avsg.2025.04.110_bib58","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jvs.2023.07.050","article-title":"Consensus minimum core data elements adapted to peripheral vascular intervention in the drug-eluting era: consensus report from the Registry Assessment of Peripheral Interventional Devices (RAPID) Pathways \"LEAN\" working group","volume":"78","author":"Black","year":"2023","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2025.04.110_bib59","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.jvs.2020.10.067","article-title":"Endovascular interventions for claudication do not meet minimum standards for the Society for Vascular Surgery efficacy guidelines","volume":"73","author":"Bath","year":"2021","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2025.04.110_bib60","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jvs.2022.10.025","article-title":"Early peripheral vascular interventions for claudication are associated with higher rates of late interventions and progression to chronic limb threatening ischemia","volume":"77","author":"Sorber","year":"2023","journal-title":"J Vasc Surg"}],"container-title":["Annals of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509625002936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509625002936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:33:33Z","timestamp":1752593613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890509625002936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":60,"alternative-id":["S0890509625002936"],"URL":"https:\/\/doi.org\/10.1016\/j.avsg.2025.04.110","relation":{},"ISSN":["0890-5096"],"issn-type":[{"value":"0890-5096","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary Femoropopliteal Stents: Reporting Gaps of Randomized Trials","name":"articletitle","label":"Article Title"},{"value":"Annals of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.avsg.2025.04.110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}